• 1
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 41729.
  • 2
    Chapman RWG, Arborgh BAM, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 8707.
  • 3
    Wiesner RH, La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 2006.
  • 4
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 7137.
  • 5
    Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 63944.
  • 6
    Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 3936.
  • 7
    Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215: 598603.
  • 8
    Chalasani N, Smallwood G. Idiopathic ulcerative colitis in patients with primary sclerosing colitis (sic!) undergoing orthotopic liver transplantation (OLT). Am J Gastroenterol 1998; 93: 4812.
  • 9
    Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002; 36: 2716.
  • 10
    Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression develop inflammatory bowel disease. Am J Gastroenterol 1997; 92: 27982.
  • 11
    Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 1999; 29: 1514.
  • 12
    Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 25361.
  • 13
    Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2 deficient mice. J Immunol 1997; 159: 36228.
  • 14
    Damoiseaux JG, Van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol (Praha) 1998; 44: 19.
  • 15
    Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporin A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 4009.
  • 16
    Mohamed MA, Robertson H, Booth TA, et al. Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506). Transpl Int 2000; 13(Suppl. 1): S2958.
  • 17
    Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 180817.
  • 18
    Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporin A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine response. Hum Immunol 2000; 62: 88497.
  • 19
    Wong PY, Portmann B, O'Grady JG, et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J Hepatol 1993; 17: 2847.
  • 20
    Dimitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver graft: the effect of immunosuppression. J Hepatol 1996; 24: 2537.